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Aims Flavanol-rich chocolate (FRC) is beneficial for vascular and platelet function by increasing nitric oxide bioavailability
and decreasing oxidative stress. Congestive heart failure (CHF) is characterized by impaired endothelial and increased
platelet reactivity. As statins are ineffective in CHF, alternative therapies are a clinical need. We therefore investigated
whether FRC might improve cardiovascular function in patients with CHF.
Methods
and results
Twenty patients with CHF were enrolled in a double-blind, randomized placebo-controlled trial, comparing the effect
of commercially available FRC with cocoa-liquor-free control chocolate (CC) on endothelial and platelet function in
the short term (2 h after ingestion of a chocolate bar) and long term (4 weeks, two chocolate bars/day). Endothelial
function was assessed non-invasively by flow-mediated vasodilatation of the brachial artery. Flow-mediated vasodila-
tation significantly improved from 4.98+1.95 to 5.98+ 2.32% (P ¼ 0.045 and 0.02 for between-group changes) 2 h
after intake of FRC to 6.86+ 1.76% after 4 weeks of daily intake (P ¼ 0.03 and 0.004 for between groups). No effect
on endothelial-independent vasodilatation was observed. Platelet adhesion significantly decreased from 3.9+1.3 to
3.0+1.3% (P ¼ 0.03 and 0.05 for between groups) 2 h after FRC, an effect that was not sustained at 2 and 4 weeks.
Cocoa-liquor-free CC had no effect, either on endothelial function or on platelet function. Blood pressure and heart
rate did not change in either group.
Conclusion Flavanol-rich chocolate acutely improves vascular function in patients with CHF. A sustained effect was seen after
daily consumption over a 4-week period, even after 12 h abstinence. These beneficial effects were paralleled by
an inhibition of platelet function in the presence of FRC only.
Trial Registration ClinicalTrials.gov Identifier: NCT00538941
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Introduction
Cocoa consumption exerts several beneficial effects on cardiovas-
cular health.1 Epidemiologically, its consumption is inversely corre-
lated with blood pressure (BP) and all-cause mortality,2 which has
been recently confirmed in a large population-based study.3
However, there are no large-scale prospective morbidity and mor-
tality trials evaluating the effect of cocoa so far, but smaller rando-
mized studies convincingly proved beneficial short-term effects on
cardiovascular surrogates, namely on endothelial function.1
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Endothelial dysfunction is a pathophysiological condition, asso-
ciated with premature atherothrombotic disease.4 Diminished
NO bioavailability and increased oxidative stress are among the
most important features of endothelial dysfunction.5 Endothelial
function can be assessed non-invasively by ultrasound-guided
measuring of flow-mediated dilatation (FMD) of the brachial
artery. It correlates with coronary endothelial function and is pre-
dictive of future coronary events.6 –8
Congestive heart failure (CHF) is a prevalent condition, repre-
senting the final stage of most cardiovascular diseases and is asso-
ciated with high morbidity and mortality.9 Patients with CHF
typically show endothelial dysfunction, increased oxidative stress,
and baroreceptor dysfunction.10 Moreover, patients with impaired
FMD are at increased risk for cardiovascular events and death10
complications of atherosclerosis that involve increased platelet ac-
tivation. Indeed, many complications in HF are thrombus-related
and increased platelet activation has been observed in CHF.11
Cocoa acutely improve NO-dependent vasodilatation in healthy
humans12 and in patients with cardiovascular risk factors, including
diabetes, both in the forearm circulation13–15 and in coronary
arteries.16 Congestive heart failure is a very late stage of most
forms of cardiovascular disease. At that stage, many cardiovascular
alterations are irreversible. For instance, lowering of low-density
lipoproteins by HMG coenzyme reductase inhibitors does not
longer reduce the event rates even in patients with ischaemic car-
diomyopathy.17,18 Thus, alternative treatment options have to be
explored in these high-risk patients. Due to its potential to
enhance NO bioavailability and its antioxidative properties,
flavanol-rich chocolate (FRC) might be beneficial in CHF patients.
It was thus the aim of this double-blind, placebo-controlled study
to evaluate both the acute (2 h after ingestion) and the longer-
term (at 2 and 4 weeks) effects of FRC when compared with a
cocoa-liquor-free control chocolate (CC) on endothelial and
platelet function in patients with CHF.
Methods
Subjects
Twenty-two patients with stable CHF (NYHA ≥ II) and ejection frac-
tion ,50% have been randomized. Exclusion criteria were: decompen-
sated HF, unstable angina pectoris, smoking, creatinine .200 mmol/L,
alanine aminotransferase or aspartate aminotransferase .150 IU, dia-
betes mellitus, obesity (body mass index .30 kg/m2), symptomatic
hypotension, BP . 160/100 mmHg, known allergies to compounds
of study chocolate or placebo, respectively, history of gastric ulcer
or bleeding, venous thrombosis or pulmonary embolism, history of in-
fectious disease or systemic inflammatory diseases, malignant tumours
(unless cured or in remission for more than 5 years), concomitant
vitamin supplements, as well as participation in another study within
the last month. Two patients dropped out during follow-up (one
patient withdrew consent because of personal reasons and one
patient was excluded due to ventricular fibrillation, terminated by an
internal defibrillator; this event was considered unrelated to the
study protocol). Twenty patients were included into the final analysis.
Flavanol-rich and CC were prepared by Nestle´. Both were wrapped
identically and randomization was done by an organization independ-
ent of the study group (InterCorNet, Zu¨rich, Switzerland).
All patients gave signed informed consent. The study was performed
at the University Hospital of Zurich, and the study protocol approved
by the local Ethics Committee and conducted according to the Declar-
ation of Helsinki. Patients were recruited from the HF outpatient clinic.
Experimental protocol
All patients were instructed to refrain from flavanol-rich food for 24 h
and fast for at least 8 h before baseline examinations, which were
always performed in the morning. After a short clinical examination
and blood sampling, baseline measurements were performed. Blood
pressure was measured three times with a validated automatic BP
device (OMRON Mit Elite Plus). The mean of the last two measure-
ments was recorded. Following the first assessment, the participants
were randomized to receive either 40 g of FRC or 28.4 g of CC
(weight matched for fat and sugar content to the dark chocolate),
which had to be ingested within 10 min. A nurse not directly involved
in the study distributed study chocolate to the patient.
The study design is summarized in Figure 1. Primary endpoint of the
study was endothelial function measured as FMD of the brachial artery.
Secondary endpoints were baroreceptor function, platelet adhesion,
and oxidative stress parameters. To assess the short-term effects,
2 h after the baseline visit, endothelial and baroreceptor function
and platelet adhesion measurements were repeated. Afterwards, all
participants obtained a box with blinded FRC or CC bars, respectively,
and were instructed to ingest one bar twice a day and to continue their
normal daily diet. Endothelial, platelet, and baroreceptor functions
were reassessed at 2 and 4 weeks to assess the longer-term effect.
Measurements were performed after overnight fasting (at least 8 h)
to assess thoroughly the long-term effects.
Study chocolate and control
The FRC bars consisted of a commercially available preparation
(Nestle´ Noir IntenseTM). This chocolate contains 10.5 g of sugar and
17.9 g of fat per 40 g serving with 70% cocoa content. The catechin
and epicatechin concentrations were 0.27 and 0.9 mg/g, respectively
(as measured by high-performance liquid chromatography), with
total polyphenol content (as measured by the Folin–Ciocalteau
method) of 15.6 mg epicatechin equivalents/g (data from Nestle´ Re-
search Center, Lausanne, Switzerland). Nestle´ also supplied the
cocoa-liquor-free chocolate CC, given in 28.4 g portions to match
carbohydrate and fat content to 40 g dark chocolate. The chocolate
bars were identically wrapped to avoid any potential bias for the
patient or examinators.
Flow-mediated vasodilatation
Endothelial function was assessed by measurement of the FMD of the
brachial artery as described previously.7,19 In brief, while patients were
in the supine position, at rest, in a quiet air conditioned room, a two-
dimensional scan of the left brachial artery was obtained in a longitu-
dinal section between 2 and 10 cm above the elbow, using a high-
resolution 10 MHz linear array transducer and a high-resolution ultra-
sound system (Siemens Acuson X300). The transducer was kept in the
same position during examination with the help of a stereotactic clamp
to ensure consistency of the image. The analogue video signal was
acquired with a video processing system, which computes the artery
diameter in real-time (FMD Studio, Pisa, Italy).20
One minute after acquisition of the basal diameter, a wrist cuff was
inflated to 220 mmHg for 5 min. Immediately after release, arterial
diameter was continuously recorded during reactive hyperaemia and
flow velocity was measured. Baseline vessel size was considered as
the mean of the measures obtained during the first minute. Flow-
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mediated vasodilatation was calculated as the maximal per cent in-
crease in diameter above the baseline. Endothelial-independent dila-
tion was measured after glyceryl trinitrate (0.4 mg sublingual,
Pohl-Boskamp, Germany) sublingual application by recording arterial
diameter continuously. The reproducibility of our laboratory has
been published previously.21
Shear stress-dependent platelet adhesion
Shear stress-dependent platelet adhesion was assessed using the cone
and platelet analyzer. In brief, citrated whole blood (200 mL) was cir-
culated in polystyrene wells at a shear rate of 1875 s21 for 2 min with a
rotating Teflon cone, as described previously.22 Wells were washed,
stained with May–Gru¨nwald, and analysed with a microscope con-
nected to an image analysis system. Results were expressed as the per-
centage surface covered by platelets and as the size of the platelet
aggregates (ImageJ 1.31, National Institute of Health, USA).
Baroreflex function
Heart rate (HR) was measured together with BP using an ECG and
Dynamap (Critikon, Inc., Tampa, FL, USA), respectively. Data were
stored and analysed off-line with MatLab (The Math Works, Inc.,
Natrick, MA, USA). The assessment of baroreceptor function was
done off-line with the a-coefficient method as described previously.23
Due to technical reasons, these data were available in 11 patients only
(6 in the group receiving FRC and 5 in the control group).
Biomarkers of oxidative stress
Serum samples were analysed at the Antioxidant Research Laboratory
of the Unit of Human Nutrition INRAN in Rome, Italy, and the ana-
lyses were performed before unblinding of the study. The TRAP
(total radical-reducing antioxidant potential) method is based on the
protection provided by antioxidants against the fluorescence decay
of R-phycoerythrin (lag phase) during a controlled peroxidation
reaction.
The ferric-reducing antioxidant potential assay is based on reduction
in the Fe3+–TPTZ complex to the ferrous form at low pH monitored
at 595 nm by a Sunrise absorbance plate reader (Tecan Italia).
Total 8-iso-prostaglandin F2a (8-iso-PGF2a) was quantified in
serum samples with a direct 8-iso-PGF2a enzyme immunoassay kit
(Assay Designs Inc., Ann Arbor, MI, USA). All three tests have been
described in detail earlier.16
Assessment of plasma flavanol
concentrations
The plasma samples were sent to the Nestle´ Research Centre,
Lausanne, Switzerland, where the analyses were performed. The
bioavailability of flavanols was assessed by identifying (2-
)-epicatechin, 3′-O-methyl-epicatechin, 4′-O-methyl-epicatechin, and
procyanidin B2 in plasma samples using a Waters Acquity Ultra-
PerformanceTM liquid chromatography system (Waters, Baden,
Switzerland) with fluorimetric detection. Prior to the chromato-
graphic analysis, the plasma samples were treated by off-line SPE
according to the method described by Unno et al.24 with some
modification.
The limits of quantification for (2)-epicatechin, 3′-O-methyl-epica-
techin, 4′-O-methyl-epicatechin, and procyanidin B2 in plasma
samples were 100, 25, 25, and 50 nM respectively. The overall recov-
ery tested at three different concentrations was 84, 93, 94, and 78% for
(2)-epicatechin, 3′-O-methyl-epicatechin, 4′-O-methyl-epicatechin,
and procyanidin B2, respectively.
Statistical analysis
The change in FMD was defined as a primary endpoint. The power
calculation was based upon results of earlier studies in our labora-
tory. An FMD d of 1.5% and a standard deviation of 1.5% for
FRC vs. control at 4 weeks were hypothesized. For a significance
level of 5%, 10 patients per treatment group were assumed to be
needed to reach a statistical power of 80%. The data were
checked for normal distribution and most data were considered nor-
mally distributed. Therefore, data were expressed as mean+ stand-
ard deviation. To assess intra- and intergroup changes for FMD at
any time points, the Wilcoxon test was used. Additionally, we com-
puted an analysis of covariance (ANCOVA) to assess the effect of
Figure 1 Study design. Measurements performed at all visits: flow-mediated vasodilatation, baroreceptor function, platelet function, blood
sampling, and clinical examination. Baseline visit and long-term effect visits are performed after fasting overnight. No chocolate bars were
ingested on the examination day (except for acute effect measurements). n ¼ actual sample size.
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treatment while correcting for the baseline values. The rest of the
data were analysed by paired and unpaired Student’s t-test, and
the Wilcoxon test as appropriate. All tests were two-sided and ana-
lysis was per protocol. A P-value of ,0.05 was considered statistic-
ally significant. Statistics were performed using SPSS 17 for Mac OS
X.
Results
Clinical characteristics
Baseline characteristics and medications of the study population
are shown in Table 1. No significant difference was found
between the two groups with the exception of a slightly lower
plasma potassium in the group assigned to FRC (4.0+0.2 and
4.2+ 0.3, P ¼ 0.05, respectively). Risk factor distribution was
similar between the groups: history of arterial hypertension (FRC
2/10 and CC 3/10), dyslipidaemia (FRC 7/10, CC 5/10), and posi-
tive family history for cardiovascular disease (FRC 7/10, CC 6/10).
According to the protocol, patients with diabetes mellitus and
smokers were not included. Patients remained clinically stable
during the study with no HF decompensation noted as also
reflected by unchanged pro-B-natriuretic peptide levels (from
898.6+ 1084.7 to 743.5+1059.3 ng/L after FRC and from
667.0+ 443.5 to 684.5+ 513.7 ng/L after CC). Weight remained
stable during the 4-week course of daily chocolate ingestion
(76.7+18.8–76.9+18.7 and 76.8+11.6–77.3+11.4 kg,
respectively).
Blood pressure and heart rate
Systolic and diastolic BP and HR were not affected in the short and
in the longer term (Tables 2 and 3). Heart rate was rather low in
this patient group, reflecting the appropriate use of b-blockers in
this population.
Laboratory parameters
In the group receiving cocoa-liquor-free chocolate, there was a
significant decrease in insulin-sensitivity as assessed by the quan-
titative insulin sensitivity check index (QUICKI; Tables 1 and 3),
interestingly, an effect not seen in the FRC group. Otherwise,
both FRC and cocoa-liquor-free CC had no immediate- or
longer-term effects on laboratory parameters. There has been
no acute or chronic impact on inflammatory a on oxidative
stress markers, including total antioxidative capacity,
ferric-reducing antioxidative capacity, or isoprostanes (Tables 2
and 3).
The slight but statistically non-significant higher plasma levels of
high-sensitivity C-reactive protein in the control group throughout
the study can be attributed to one patient with elevated C-reactive
protein levels. However, exclusion of this particular patient had no
significant influence on the primary outcome.
Polyphenol plasma levels
There was a significant increase in plasma polyphenols after inges-
tion of FRC, when compared with cocoa-liquor-free CC. Epicate-
chin concentration increased (from below detection limit to
0.69+0.28 mM, P, 0.001 for intra- and between-group
changes), whereas no plasma epicatechin were detectable before
and after CC. However, in the FRC group (2)-epicatechin meta-
bolites were only detected in the short term (2 h after ingestion)
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Table 1 Clinical characteristics of the study
population (n 5 20)
FRC (n5 10) CC (n5 10)
Age (years) 60.3+10.1 58.1+11.9
Male/female 8/2 9/1
Aetiology (ischaemic/not
ischaemic)
5/5 5/5
Time from CHF diagnosis (years) 6.1+3.9 6.7+5.7
Ejection fraction (%) 29.9+9.9 34.7+8.8
FMD (%) 4.98+1.95 5.06+2.29
Weight (kg) 76.7+18.8 76.8+11.6
BMI (kg/m2) 25.9+5.1 25.6+3.5
Systolic BP (mmHg) 109.5+13.0 113.2+18.1
Diastolic BP (mmHg) 65.8+8.4 68.0+12.3
HR (b.p.m.) 67.6+11.7 60.1+10.5
Creatinine (mmol/L) 94.3+11.2 100.6+26.3
Sodium (mmol/L) 138.0+2.2 139.1+3.3
Potassium (mmol/L) 4.0+0.2 4.2+0.3
Hb (g/dL) 14.2+1.0 13.6+1.6
Platelets (103/mL) 226.5+39.7 231.2+66.9
Glucose (mmol/L) 6.4+1.1 5.8+1.2
QUICKI 0.33+0.05 0.33+0.04
HbA1c (%) 5.9+0.4 5.8+0.4
Total cholesterol (mmol/L) 4.7+1.1 5.0+1.5
HDL-cholesterol (mmol/L) 1.2+0.3 1.3+0.3
LDL-cholesterol (mmol/L) 2.5+1.0 2.9+1.2
Triglycerides (mmol/L) 2.1+0.9 1.7+0.8
ALT (U/L) 31.6+7.6 29.6+10.1
AST (U/L) 42.0+22.4 29.1+10.2
Pro-BNP (ng/L) 898.6+1084.7 667.0+443.5
High-sensitivity C-reactive protein
(mg/L)
1.4+1.4 4.4+4.4
Medication
ACE-inhibitor/ARB 10/10 10/10
b-Blocker 10/10 10/10
Diuretics 8/10 6/10
Calcium antagonist 1/10 0/10
Aspirin (100 mg) 4/10 3/10
Clopidogrel 1/10 2/10
Statin 7/10 4/10
Oral anticoagulation 5/10 7/10
Molsidomin 1/10 1/10
Digoxin 1/10 3/10
Antiarrhytmics 0/10 3/10
FRC, flavanol-rich chocolate; CC, control chocolate; FMD, flow-mediated
dilatation; BMI, body mass index; BP, blood pressure; HR, heart rate; Hb,
haemoglobin; QUICKI, quantitative insulin sensitivity check index; HDL, high
density lipoprotein; LDL, low density lipoprotein; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; BNP, B-natriuretic peptide; ACE,
angiotensin-converting enzyme, ARB, angiotensin receptor blocker.
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but not at the end of the 4-week treatment period (12 h after the
last ingestion) (Table 2).
Flow-mediated dilatation of the brachial
artery
Baseline brachial artery diameter and baseline FMD were similar
in both groups. Two hours after ingestion of 40 g of FRC, FMD
increased from 4.98+ 1.95 to 5.98+2.32% (P ¼ 0.045 and 0.02
for between groups), whereas the 28.4 g of CC showed no
effect (from 5.06+ 2.29 to 4.47+1.5%; P ¼ 0.44). Similarly,
chronic daily intake of 80 g of FRC resulted in a significant ameli-
oration of endothelial dysfunction both after 2 (from 4.98+1.95
to 5.82+ 1.54%; P ¼ 0.045 and 0.33 for between groups) and
after 4 weeks (from 4.98+ 1.95 to 6.86+1.76%; P ¼ 0.027
and 0.004 for between groups), despite a 12 h refrain from
flavanol-rich food before the follow-up measurements of FMD.
Again, CC did not change FMD over the entire time course of
up to 4 weeks (Figure 2). In the ANCOVA model to assess
the effect of FRC while correcting for the baseline FMD
values, the between-group comparison after 4 weeks is even
more pronounced (P, 0.0001). Nitroglycerin-induced endothe-
lial-independent vasodilatation was not different between the
groups at all time (Tables 2 and 3); additionally, reactive hyper-
aemia was not different between visits or within the treatment
groups (data not shown). In addition to the improvement in
endothelial function, FRC significantly increased baseline brachial
artery diameter 2 h after ingestion (from 5.2+ 1.2 to 5.4+
1.1 mm; P ¼ 0.001 and P ¼ 0.01 for between groups), while in
the control group, the baseline diameter did not change (from
5.4+0.8 to 5.4+ 0.8 mm, respectively; P ¼ 0.10).
Baroreceptor function
Flavanol-rich chocolate as well as cocoa-liquor-free CC did not sig-
nificantly influence baroreceptor function in patients with HF.
There were no acute and chronic changes in baroreceptor sensitiv-
ity in both the high- and low-frequency ranges (Tables 2 and 3).
Platelet function
Flavanol-rich chocolate intake acutely improved platelet function.
Two hours after chocolate intake, platelet adhesion was significant-
ly reduced from 3.9+1.3 to 3.0+ 1.3% (P ¼ 0.03 and 0.05 for
between groups), whereas no change could be observed in the
control group (from 3.3+ 1.9 to 3.5+1.7%, respectively;
Figure 3). However, no significant effect of FRC on platelet adhe-
sion was found at 4 weeks after chronic ingestion of FRC after a
12 h refrain period from flavanol-rich food (from 3.9+ 1.3 to
4.1+1.5%; P ¼ 0.70 and P ¼ 0.43 for between groups; Table 3).
Discussion
In the present study, we, for the first time, report a significant and
specific effect of commercially available FRC on endothelial and
platelet function, in patients with CHF. Interestingly, chocolate
not only improved this important cardiovascular surrogate
marker acutely, but even more so, after longer-term ingestion
for up to 4 weeks. Such a vascular positive effect of an orally
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Table 2 Acute effect (after 2 h) of flavanol-rich chocolate and control chocolate
FRC (n5 10) CC (n 5 10) Between-group P-value
Baseline 12 h Baseline 12 h
Diameter (mm) 5.15+1.23 5.41+1.11* 5.43+0.77 5.38+0.76 0.01
FMD (%) 4.98+1.95 5.98+2.32* 5.06+2.29 4.47+1.5 0.02
GTN (%) 15.6+5.1 13.1+2.6 13.6+3.1 12.0+3.7 0.48
Platelet adhesion (%) 3.87+1.32 2.99+1.31* 3.30+1.86 3.49+1.66 0.05
SBP (mmHg) 109.5+13.0 112.5+12.9 113.2+18.1 112.3+14.1 0.32
DBP (mmHg) 65.8+8.4 70.2+9.1 68.0+12.3 69.1+10.3 0.39
Heart rate (b.p.m.) 67.6+11.7 62.9+7.4 60.1+10.5 60.3+10.9 0.12
BRS HF (n ¼ 6) 27.4+14.4 29.9+19.6 21.0+22.3 21.5+21.7 0.83
BRS LF (n ¼ 5) 16.7+16.3 17.1+13.9 14.9+19.8 22.6+27.2 0.71
LF/HF (n ¼ 5) 1.0+0.6 5.7+13.7 1.0+0.6 1.3+0.7 0.18
Glucose (mmol/L) 6.4+1.1 5.5+0.46* 5.8+1.2 5.1+0.43* 0.07
High-sensitivity C-reactive protein (mg/L) 1.4+1.4 1.5+1.4 4.4+4.4 4.4+4.4 0.90
Flavanols (mmol/L) 0.00+0 0.69+0.28* 0.00+0 0.00+0 ,0.001
TRAP (mmol/L) 1667+299 1749+297 1599+219 1651+225 0.19
FRAP (mmol/L) 1412+235 1441+245 1273+173 1325+212 0.78
8-Isoprostanes (pg/mL) 865.2+228.7 800.3+41.6 831.3+36.9 812.0+38.6 0.46
FMD, flow-mediated dilatation; GTN, glyceryl trinitrate (nitroglycerin); SBP, systolic blood pressure; DBP, diastolic blood pressure; BRS, baroreceptor sensitivity; LF, low
frequency; HF, high frequency; TRAP, total reducing antioxidative potential; FRAP, ferric-reducing antioxidative potential.
*P, 0.05 vs. baseline.
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available molecule is not trivial in CHF as unexpectedly statins
proved to be ineffective in this patient population.17,18
While most studies, so far, investigated only the acute effects of
FRC on endothelial function,1 we here report long-term effects
with daily ingestion of FRC using a double-blind randomized
design, rarely applied in nutritional research. In addition, this is
the first study on the effect of chocolate in patients with advanced
heart disease such as CHF. Of note, CHF is associated with endo-
thelial dysfunction, a condition confirmed in our patient popula-
tion. Indeed, FMD averaged about 4%, which is markedly lower
than that observed in healthy controls.25 The molecular mechan-
isms of endothelial dysfunction in CHF might involve increased
levels of cytokines, impaired endothelial-receptor-signal transduc-
tion pathways, and increased angiotensin-converting enzyme
activity.26– 29 Furthermore, neurohumoral activation and increased
levels of endothelium-derived vasoconstrictors occurs in CHF.30 In
addition, CHF is associated with enhanced generation of reactive
oxygen species and oxidized LDL, further counteracting vasodila-
tor properties of NO. Therefore, the fact that cocoa polyphenols
improve endothelial function by increasing NO synthase (NOS) ac-
tivity and by exerting antioxidative capacity might be of importance
for HF patients, especially as there is a strong association between
endothelial dysfunction and cardiovascular morbidity and mortality
in these patients.10 Finally, CHF patients, particularly at advanced
stages, are prone to weight loss, anaemia, and cachexia, making nu-
tritional issues important in the management of such patients.
In our study, ingestion of FRC was followed by a marked and sig-
nificant increase in (2)-epicatechin plasma concentrations. In par-
allel, FMD improved significantly in the flavanol, but not in the
control group. This effect likely involves increased NO bioavailabil-
ity, since it is reduced in CHF,31 and ingestion of cocoa high in fla-
vanols rapidly enhances the pool of bioactive NO and improves
FMD in patients with hypertension or diabetes.15,32 Furthermore,
after the infusion of L-NMMA, an inhibitor of the NO synthesis,
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Table 3 Long-term effect (4 weeks) of flavanol-rich chocolate or control chocolate
FRC (n5 10) CC (n 5 10) Between-group P-value
Baseline 14 weeks Baseline 14 weeks
Brachial artery diameter (mm) 5.15+1.23 5.25+1.22 5.43+0.77 5.28+0.76 0.02
FMD (%) 4.98+1.95 6.86+1.76* 5.06+2.29 3.92+1.89 0.004
GTN (%) 15.6+5.1 13.4+4.2 13.6+3.1 13.7+3.4 0.06
Platelet adhesion (%) 3.86+1.32 4.07+1.52 3.30+1.86 3.27+1.77 0.43
Weight (Kg) 76.7+18.8 76.9+18.7 76.8+11.6 77.3+11.4 0.33
SBP (mmHg) 109.5+13.0 106.7+7.2 113.2+18.1 117.8+20.5 0.12
DBP (mmHg) 65.8+8.4 68.1+8.9 68.0+12.3 69.8+8.6 0.87
Heart rate (b.p.m.) 67.6+11.7 68.3+7.3 60.1+10.5 59.6+11.3 0.71
BRS HF (n ¼ 6) 27.4+14.4 21.2+10.9 21.0+22.3 19.1+9.1 0.53
BRS LF (n ¼ 5) 16.7+16.3 15.4+12.3 14.9+19.8 15.2+18.4 0.40
LF/HF (n ¼ 5) 1.0+0.6 3.3+3.8 1.0+0.6 2.1+2.1 0.31
Creatinine (mmol/L) 94.3+11.2 98.6+17.8 100.6+26.3 103.8+28.6 0.24
Sodium (mmol/L) 138.0+2.2 138.8+1.0 139.1+3.3 139.0+2.9 0.38
Potassium (mmol/L) 4.0+0.2 4.0+0.3 4.2+0.3 4.0+0.3 0.07
Glucose (mmol/L) 6.4+1.1 6.4+0.8 5.8+1.2 6.2+1.7 0.13
QUICKI 0.33+0.05 0.32+0.04 0.33+0.04 0.31+0.05* 0.21
HbA1c (%) 5.9+0.4 5.8+0.2 5.8+0.4 5.9+0.4 0.15
ALT (U/L) 31.6+7.6 32.4+7.0 29.6+10.1 28.7+8.9 0.14
AST (U/L) 42.0+22.4 35.5+14.1 29.1+10.2 30.9+13.5 0.43
Pro-BNP (ng/L) 898.6+1084.7 743.5+1059.3 667.0+443.5 684.5+513.7 0.25
High-sensitivity C-reactive protein (mg/L) 1.4+1.4 1.13+1.04 4.4+4.4 4.55+7.1 0.80
TC (mmol/L) 4.7+1.1 4.8+1.1 5.0+1.5 5.1+1.3 0.91
HDL-C (mmol/L) 1.2+0.3 1.3+0.26 1.3+0.3 1.3+0.26 0.03
LDL-C (mmol/L) 2.5+1.0 3.1+0.7 2.9+1.2 2.5+1.2 0.71
Triglycerides (mmol/L) 2.1+0.9 1.9+1.2 1.7+0.8 1.7+0.43 0.51
TRAP (mmol/L) 1667+299 1728+259 1599+219 1696+242 0.47
FRAP (mmol/L) 1412+235 1446+269 1273+173 1331+230 0.79
8-Isoprostanes (pg/mL) 865.2+228.7 790.7+35.7 831.3+36.9 783.5+46.0 0.52
FMD, flow-mediated dilatation; GTN, glyceryl trinitrate (nitroglycerin); SBP, systolic blood pressure; DBP, diastolic blood pressure; BRS, baroreceptor sensitivity; LF, low
frequency; HF, high frequency; QUICKI, quantitative insulin-sensitivity check index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BNP, B-natriuretic peptide;
TC, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TRAP, total reducing antioxidative potential; FRAP, ferric-reducing
antioxidative potential.
*P, 0.05 vs. baseline.
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the increase in plasma NO levels as well as the amelioration of
endothelial dysfunction associated with cocoa are blunted.32 More-
over, a diet high in flavanols has been associated with a high urinary
excretion of NO metabolites33 and purified (2)-epicatechin has
been shown to mimic the endothelial effects of flavanol-rich
cocoa.33 In the short term, flavanols inhibit the inactivation of
NO by free radicals via inhibition of NADPH oxidase, while in
the long term, they seem to be able to express higher levels of
protein eNOS.34 Furthermore, pure (2)-epicatechin ingestion
not only augments NO bioavailability, but also reduces the
plasma levels of endothelin-1, a potent endothelium-derived
vasoconstrictor.35
Besides their effects on endothelial NOS expression, cocoa fla-
vanols also exert antioxidant effects in vitro, which could contribute
to the results of our study. In humans, it has been shown that
cocoa is able to counteract lipid peroxidation, thus lowering the
levels of plasma F2-isoprostanes, important markers of in vivo
lipid peroxidation,36 as well as plasma levels of oxLDL,37 and
increases overall antioxidant capacity.38 Although not obvious in
the current study, we showed that in young healthy smokers, the
same commercially available chocolate as used in the present
study was able not only to improve endothelial function but also
to improve antioxidant status.39 We also evaluated the effect of
the same commercially available chocolate on cardiac transplant
recipients, where we demonstrated a reduction in oxidative
stress, as assessed by plasma isoprostanes; this was paralleled by
coronary vasodilatation, improvement in coronary vascular func-
tion, and decreased platelet adhesion.16
Beyond the acute effects on endothelial function, the sustained
and even more pronounced effects of chronic cocoa ingestion
were remarkable. Indeed, endothelial function was further
improved after 2 and particularly after 4 weeks of daily ingestion
of 80 g of FRC. It is of note that endothelial function measurements
were performed in the morning after overnight fasting; thus, an
acute effect of chocolate in these measurements can be excluded.
Indeed, in line with this assumption, both at 2 and 4 weeks, (2-
)-epicatechin and its methyl metabolites were no longer detectable
in plasma at the time of vascular function studies. Therefore,
chronic flavanol supplementation must have changed the biology
of the brachial artery and endothelial cells, in particular in the
CHF patients studied. Although, we do not have a mechanistic
prove, flavanols most likely must have induced the expression of
endothelial NOS, an effect that was sustained beyond the short
half-life of these cocoa-derived nutrients. In line with this interpret-
ation, brachial artery diameter increased 2 h after ingestion of FRC.
Furthermore, plasma levels of oxidative stress markers as well as of
C-reactive protein were similar at 2 and 4 weeks as they had been
at baseline excluding a major contribution of reactive oxidant
species. Finally, endothelium-independent relaxations to nitrogly-
cerin were unaffected by the dietary intervention.
The improvement in platelet function shortly after cocoa inges-
tion confirms our previous studies in young healthy smokers39 and
heart transplant recipients.16 However, we were not able to show
Figure 2 Effect of flavanol-rich and control chocolate, respectively endothelial function (measured by FMD). Two hours after ingestion of
flavanol-rich chocolate, FMD increased from 4.98+1.95 to 5.98+ 2.32% whereas the control chocolate showed no significant effect (from
5.06+2.29 to 4.47+ 1.5%). Similarly, chronic daily intake of 80 g of flavanol-rich chocolate resulted in a significant amelioration of endothelial
dysfunction after 4 weeks (from 4.98+1.95 to 6.86+ 1.76%). *P, 0.05.
Figure 3 Acute effect of flavanol-rich and control chocolate,
respectively, on platelet adhesion. P ¼ 0.03 for flavanol-rich choc-
olate after 2 h compared with baseline.
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any long-term effect after 2 or 4 weeks. This may be due to the fact
that blood samples were collected after an overnight fast, and thus,
the polyphenols had already been metabolized and excreted as
reflected by the lack of detection of these substances in the
blood samples. Our findings are not surprising, since platelets
are anucleated cells and hence unable to induce protein produc-
tion, for instance, an increased transcription and translation of
endothelial NOS expression. Hence, it appears that flavanols can
activate NO release from platelets as previously described,40
but—in contrast to endothelial cells—are unable to exert sus-
tained effects in these anucleated cells.
Neurohumoral activation, in particular activation of the sympa-
thetic nervous system, is a hallmark of CHF. Thus, we further
investigated the effect of FRC on baroreceptor function by the
a-coefficient method. However, no effect of the dietary
intervention has been noted, neither in the short nor in the long
term. This is surprising, since NO has been involved in barorecep-
tor signalling.41 An explanation might be the use of b-blocking
agents in all of our patients according to guidelines, thus masking
a possible effect of FRC. Alternatively, the limited number of
observations may also contribute to the negative findings, as baror-
eflex function was only measured in 11 patients.
Epidemiological and small intervention studies suggest a small,
but distinct BP-lowering effect of chocolate consumption.2,3,42,43
However, these studies were performed in patients with elevated
or mildly elevated BP. Moreover, the effect of BP lowering was
higher in subjects with higher baseline BP.43 As it is typical in
CHF, baseline BP of our patients was low and averaged 110/
65 mmHg. We did not observe any relevant effect of FRC con-
sumption on systolic or diastolic BP, neither acutely nor after 2
and 4 weeks, despite a substantial increase in plasma epicatechin
levels and that of its metabolites. This might be explained by the
low baseline BP as well as by the fact that antihypertensive drugs
had been used. Intervention studies demonstrated improved
insulin sensitivity after chocolate consumption, especially in
hypertensives.14,42 Interestingly, in this study, we observed a
decrease in insulin sensitivity after 4 weeks in the control group,
a decrease not seen in patients consuming FRC. This may poten-
tially point towards an additional beneficial effect of FRC in CHF
patients. It is of note that despite the high caloric load of our com-
mercially available FRC, no weight gain and no change in blood
lipids were noted.
There are some limitations of the study. We did not control for
habitual food intake, especially for other cocoa products. Further-
more, patients were free to schedule study chocolate intake; thus,
other foods might have influenced bioavailability. Although we
think it is unlikely, we cannot exclude that the results are biased
by the individuals’ diet. We are aware that our results are based
on a rather small sample size; thus, effects on secondary endpoints
such as BP, oxidative stress parameters, and others might not have
been detected.
In conclusion, this is the first study demonstrating beneficial car-
diovascular effects of commercially available FRC in patients with
CHF. Flavanol-rich chocolate not only led to peripheral vasodilata-
tion, improvement in endothelial function, and enhancement in
platelet function shortly after chocolate ingestion but also to an
amelioration in endothelial function in the long term after 2 and
4 weeks of daily chocolate ingestion. It is of note that endothelial
function was improved on top of optimal medical treatment with
drugs known to improve vascular function alone.
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